Merck and Daiichi Sankyo forge $5.5 billion cancer drug alliance
Merck, a global pharmaceutical giant, has inked a partnership with Japanese firm Daiichi Sankyo, valuing at $5.5 billion, to co-develop three advanced cancer therapies. Depending on the success of these pioneering cell-targeted treatments, the agreement could garner up to $22 billion for Daiichi. This partnership triggered a significant positive response in......

